EpicentRx

EpcentRx is a patient-oriented oncology company developing novel immunotherapy mechanisms that are applicable to different patient populations and tumor types with minimal toxicity, enabling optimal quality of life during treatment. Through two distinct technology platforms, each targeting different parts of the immune system, the company is developing drug candidates designed to be used alone or in combination with other therapies to combat cancer. RRx-001 is a next-generation small-molecule immunotherapy developed by EpcentRx. The company's lead program is one of a series of new drugs derived from dinitroazetidine, which downregulates CD47-SIRPα to alter the tumor microenvironment and optimize immune response, and has been tested in multiple clinical trials, including an ongoing Phase 3 study in small cell lung cancer. The company is also advancing several programs through its Smart Virus platform.